Eli Lilly's Foundayo Sees Modest Early Uptake Amid Strong Competition from Novo Nordisk's Wegovy

Eli Lilly received U.S. approval for its oral weight-loss pill Foundayo on April 1, 2026. Prescriptions could be entered through LillyDirect immediately, with product shipping beginning on April 6 and broad retail and telehealth availability commencing on April 9. In its debut week, Foundayo was prescribed 1,390 times; in the second week after launch, prescriptions rose to 3,707, according to IQVIA data cited by analysts.

Reuters

Novo Nordisk’s oral obesity medication Wegovy entered the U.S. market in January 2026, giving it a first-mover advantage. Wegovy recorded 3,071 prescriptions in its first week and accelerated to 18,410 prescriptions in its second week, illustrating a substantially larger early uptake than Foundayo.

Reuters

The primary companies involved are Eli Lilly and Novo Nordisk. RBC Capital Markets analyst Trung Huynh and J.P. Morgan analyst Chris Schott provided market commentary on the launch dynamics. Their observations reflect investor interest in whether Foundayo can erode Novo’s market share. Investors are closely monitoring the launch.

Reuters

The prescription gap between the two drugs is pronounced: Foundayo’s 3,707 second-week prescriptions contrast with Wegovy’s 18,410. Correspondingly, Eli Lilly’s shares were trading 1.5 % lower before the market opened, while Novo Nordisk’s U.S.-listed shares rose 2 % in the same period.

Reuters

Lilly cautioned that early weekly prescription counts are not fully comprehensive and may not capture the full breadth of pharmacy partners. The company said the figures should be interpreted over time rather than as a final count, emphasizing a longer-term perspective.

Reuters

RBC analyst Trung Huynh warned that early comparisons may be immaterial but suggested that Foundayo’s uptake could be perceived negatively. J.P. Morgan analyst Chris Schott said the slower ramp is expected because Wegovy entered the market earlier and enjoys stronger brand recognition. Both analysts imply that Foundayo faces a challenging path to achieve parity with Wegovy’s early performance.

Reuters

• “While we believe comparisons early into launch should be considered immaterial, Foundayo's uptake this week is likely to be received negatively,” — Trung Huynh, RBC Capital Markets analyst

Reuters

• “Morgan analyst Chris Schott, adding it is not surprising given Wegovy's advantages in time to market and brand recognition.” — Chris Schott, J.P. Morgan analyst

Reuters

• “best interpreted over time rather than as a complete count” — Eli Lilly spokesperson (cautioned statement)

Reuters

Lilly indicated that prescription data will be evaluated over subsequent weeks to assess market penetration. Analysts are expected to track weekly prescription trends and share-price movements as additional data become available.

Reuters